Cancer
Top UK doctors warn Boris Johnson that no-deal Brexit would cause key cancer therapy supply shortages
August 2, 2019Manufacturing and Production, Medical Communications Cancer, NHS, UK, brexit, pharma
Top doctors from some of the UK’s foremost nuclear medicine associations have written a letter to recently-anointed Prime Minister Boris …
Novartis’ Kisqali reinforces overall survival benefit in postmenopausal HR+/HER2- breast cancer
August 1, 2019Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma
New Phase 3 evidence has emerged on the efficacy of Novartis’ Kisqali (ribociclib) in combination with AstraZeneca’s Faslodex (fulvestrant) in …
Lilly’s Verzenio combo shows additional breast cancer survival benefit in new Phase 3 data
July 31, 2019Research and Development Cancer, Eli Lilly, Verzenio, breast cancer, pharma
Eli Lilly has revealed new Phase 3 data on its CDK4 & 6 inhibitor Verzenio (abemaciclib), demonstrating its efficacy in …
Bayer and Orion’s Nubeqa secures FDA approval in non-metastatic castration-resistant prostate cancer
July 31, 2019Research and Development, Sales and Marketing Bayer, Cancer, Nubeqa, orion, pharma, prostate cancer
The FDA has awarded approval under its Priority Review pathway to Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate …
Bayer’s Vitravki poised to become first tumour-agnostic therapy in EU following CHMP recommendation
July 30, 2019Manufacturing and Production, Sales and Marketing Bayer, CHMP, Cancer, EU, Vitrakvi, pharma
Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) could be set to become the European Union’s first drug approved in a tumour-agnostic …
MSD’s Keytruda combo hits primary endpoint at Phase 3 in triple-negative breast cancer
July 30, 2019Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma
MSD’s blockbuster anti-PD-L1 immunotherapy Keytruda (pembrolizumab) has impressed in newly released Phase 3 data; the company announced that, when combined …
Roche’s Tecentriq combo recommended in Europe for non-small cell lung cancer
July 29, 2019Sales and Marketing Cancer, NSCLC, Roche, lung cancer, pharma, tecentriq
Riche’s blockbuster immunotherapy Tecentriq (atezolizumab) is closing in on securing yet another approval after it revealed that the drug was …
AstraZeneca’s Lynparza approved via Cancer Drugs Fund for BRCA+ gynaecological cancers
July 26, 2019Medical Communications, Sales and Marketing AstraZeneca, Cancer, Cancer Drugs Fund, NHS, NICE, UK, lynparza, pharma
NICE has published final guidance which approves AstraZeneca’s Lynparza (olaparib) for use on the NHS as a maintenance therapy for …
NICE greenlights Novartis Kisqali combo in HR+/HER2- advanced breast cancer
July 17, 2019Manufacturing and Production, Medical Communications, Research and Development Cancer, Kisqali, NICE, Novartis, UK, breast cancer, pharma
Novartis’ Kisqali (ribociclib) has secured recommendation from NICE in combination with fulvestrant, meaning the cyclin-dependent kinase 4 and 6 (CDK4/6) …
AstraZeneca’s Imfinzi gets orphan drug designation from FDA
July 12, 2019Medical Communications AstraZeneca, Cancer, Imfinzi, lung cancer, pharma
AstraZeneca’s cancer immunotherapy Imfinzi has been granted orphan drug status as a treatment for small cell lung cancer (SCLC). The …
Scottish NHS patients to access Pfizer’s Ibrance combo in HR+/HER- breast cancer following SMC recommendation
July 11, 2019Sales and Marketing Cancer, Scotland, Scottish Medicines Consortium, breast cancer, ibrance, pharma
Female NHS patients in Scotland will soon be able to access Pfizer’s cyclin-dependent kinase (CDK) 4/6 inhibitor Ibrance (palbociclib) after …
WHO leaves breakthrough cancer therapies off updated Essential Medicines List
July 10, 2019Research and Development Cancer, EML, WHO, essential medicines list, oncology, pharma, world health organization
The World Health Organization (WHO) has updated its list of essential medicines to include 28 more drugs. The WHO’s Essential …
Pierre Fabre’s triplet therapy makes strong showing in BRAF V600E-mutant metastatic colorectal cancer
July 8, 2019Research and Development, Sales and Marketing Cancer, Pierre Fabre, colorectal cancer, pharma
Pierre Fabre chose the European Society for Medical Oncology (ESMO) 21st World Congress on Gastrointestinal Cancer in Barcelona, Spain, to …
New urine test can diagnose and offer prognosis for prostate cancer
July 8, 2019Sales and Marketing Cancer, oncology, pharma, prostate cancer, urine test
A new urine test can diagnose cases of aggressive prostate cancer more quickly than invasive biopsies. The test can also …
NICE recommends Pfizer’s Vizimpro, rejects AstraZeneca’s Tagrisso, in non-small cell lung cancer
July 5, 2019Medical Communications, Sales and Marketing Cancer, NHS, NICE, Pfizer, UK, Vizimpro, lung cancer, pharma
NICE has announced its decision to recommend Pfizer’s Vizimpro (Dacomitinib) in the treatment of non-small-cell lung cancer (NSCLC) – a …
Latest content
Five Facts about cardiovascular disease
